Prevalence of Targetable Mutations in Black Patients With Lung Cancer: A Systematic Review and Meta-Analysis.

Philippos Apolinario Costa Eduardo Edelman SaulYonette PaulSunil Girish Iyer Laercio Lopes da SilvaLeonardo TamarizGilberto Lopes

Published in: JCO oncology practice (2021)

EGFR is the most frequent mutation found in Black patients, although its prevalence is lower than that in other races. Black patients have a low overall prevalence of ALK, ROS-1, and BRAF mutations. Given that disproportional eligibility for targeted therapies may be contributing to inferior outcomes, research focused on the Black population is needed to evaluate specific tumor characteristics and therapeutic strategies.

Keyphrases

end stage renal disease
ejection fraction
risk factors
chronic kidney disease
newly diagnosed
small cell lung cancer
prognostic factors
type diabetes
cell death
patient reported outcomes
dna damage
epidermal growth factor receptor
insulin resistance
oxidative stress
glycemic control